Last reviewed · How we verify
Flutiform 50/5 micrograms
Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma.
Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma. Used for Asthma maintenance therapy in adults and adolescents.
At a glance
| Generic name | Flutiform 50/5 micrograms |
|---|---|
| Sponsor | Mundipharma Research Limited |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate binds to glucocorticoid receptors in the airways, suppressing inflammatory cell recruitment and reducing production of inflammatory mediators. Formoterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and prolonging airway opening. Together, these agents provide both anti-inflammatory and bronchodilator effects for maintenance asthma control.
Approved indications
- Asthma maintenance therapy in adults and adolescents
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
Key clinical trials
- An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma (PHASE3)
- Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma (PHASE3)
- A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD (PHASE3)
- A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flutiform 50/5 micrograms CI brief — competitive landscape report
- Flutiform 50/5 micrograms updates RSS · CI watch RSS
- Mundipharma Research Limited portfolio CI